

**Wanbury Limited**

Regd. Office : BSEL Tech Park, B-wing
10th Floor, Sector-30 A,
Opp. Vashi Railway Station,
Vashi Navi Mumbai 400 703
Maharashtra, INDIA
Tel. : +91-22-6794 2222
+91-22-7196 3222
Fax : +91-22-6794 2111/333
CIN L51900MH1968PLC048455
Email : info@wanbury.com
Website : www.wanbury.com

August 6, 2025

BSE Limited PJ. Towers, Dalal Street Mumbai-400001 Script Code: 524212	National Stock Exchange of India Ltd, Exchange Plaza, Bandra Kurla Complex, Bandra (East), Mumbai -400051 Script Code: WANBURY
---	---

Dear Sir/Madam,

Sub.: Press release on Q1FY26 Un-audited Financial Results

Please find attached herewith copy of press release on Un-audited Financial Results for the quarter ended 30th June, 2025.

This is for your information and record.

Thanking you.

Yours faithfully,
For Wanbury Ltd



Jitendra J. Gandhi
Company Secretary

Encl.: a/a.





Q1FY26 PAT Surges to ₹13.5 Crore vs ₹1.0 Crore YoY

5th August, 2025, MUMBAI: Wanbury Ltd., a pharmaceutical company with a presence in the global API market and domestic branded formulations, has announced its financial results for the quarter ended 30th June, 2025.

Consolidated Q1 FY26 Financial Highlights

(Rs in Crore)						
Particulars	Q1 FY26	Q1 FY25	Y-o-Y	Q4 FY25	Q-o-Q	FY25
Revenue from Operations	163.2	131.1	24%	172.0	(5)%	599.5
EBITDA (incl. other income)	24.8	11.9	108%	31.5	(21)%	79.8
EBITDA Margin (%)	15.2%	9.1%	610 bps	18.3%	(310) bps	13.3%
PAT	13.5	1.0	1198%	20.3	(33)%	30.5
PAT Margin (%)	8.3%	0.8%	850 bps	11.80%	(350) bps	5.1%

Financial Highlights:

For the quarter ended as on 31st March 2025:

- Revenue from operations for Q1FY26 stood at ₹163.2 crore, up from ₹131.1 crore in Q1FY25, reflecting a strong YoY growth of 24%. This growth was driven by higher sales volumes in key API products such as Sertraline, supported by increased production capacity, as well as strong sales performance in the Branded Formulations segment
- EBITDA (including other income) for the quarter stood at ₹24.8 crore, compared to ₹11.9 crore in Q1FY25, registering a growth of 108%. This performance was driven by operating leverage and backward integration of key API products such as Sertraline
- PAT for the quarter stood at ₹13.5 crore, compared to ₹1.0 crore in Q1FY25, registering a growth of 1198%. This improvement was primarily driven by strong growth in Revenue and EBITDA during the quarter

Other Key Highlights:

- Wanbury Limited has successfully launched its innovative liposomal iron supplement, **Wanbury C RED** PAN India, receiving strong support from clinicians and doctors for superior anemia management. This new product offers enhanced absorption and fewer side effects, especially for women and iron-intolerant individuals, further strengthening Wanbury's leadership in gynaecology. The company had already informed the exchange about the launch, and this update highlights its robust early uptake and expanding market presence.
- Wanbury Limited's API manufacturing sites at Patalganga and Tanuku have both successfully received Good Manufacturing Practices (GMP) certification from Brazil's health authority ANVISA, following review of inspection reports and other documents. With these certifications, Wanbury continues its endeavour to supply high-quality products to regulated and premium markets.

- *Commenting on the performance, Mr. Mohan Rayana, Director of Wanbury Ltd., said,*

"Q1 FY26 marks a strong recovery for Wanbury, with both manufacturing facilities operating at healthy capacity levels post last year's planned upgradation. This has positively impacted our top line and profitability, setting a strong tone for the year ahead. The Board has also approved ₹85 crore CAPEX plan for FY26, the investments will commence towards a new production block for new APIs, product yield and solvent recovery improvements, and capacity enhancement initiatives.

In regard to the recent US tariff measures, Wanbury has only a limited exposure to the US market, which currently accounts for nearly 15% of our export revenues. This continued resilience supports our focus on operational excellence and innovation to drive growth in regulated markets

*The successful launch of **Wanbury C RED**, our advanced liposomal iron supplement, further reinforces our leadership in key therapeutic areas and supports market expansion. The product has seen encouraging early traction PAN India, with strong acceptance from clinicians*

We are committed to accelerating growth through the introduction of new products, expanding our geographic footprint, increasing capacities, and sustaining operational improvements. These efforts will help enhance margins and drive further revenue growth in the upcoming quarters."





About Wanbury Ltd.

Established in 1988, listed on the National Stock Exchange of India Ltd. (Symbol: WANBURY) and BSE Ltd. (Code: 524212). The Company has a strong presence in API global market and domestic branded Formulation with its API being exported to over 50 countries and has Pan-India Formulation presence. The Company has USFDA & EUGMP approved facilities at Tanuku (Andhra Pradesh) and Patalganga (Maharashtra).

The API product portfolio includes: Metformin, Sertraline, Tramadol, Diphenhydramine, Mefenamic acid, Paroxetine and various other products in pipeline. The company's clients include some of the leading global generic players.

In Formulations, the Company has a wide presence across major therapeutic categories like, cough and cold solutions, gynaecology, orthopaedics, nutraceuticals, gastro intestinal, anti-inflammatory & analgesics.

For more details on Wanbury Ltd.: <https://www.wanbury.com/>

For further information please contact:

Jitendra J. Gandhi
Company Secretary,
Wanbury Limited
BSEL Techpark, B' Wing, 10th Floor,
Sector 30-A, Opp. Vashi Railway Station,
Vashi, Navi Mumbai – 400 703,
Maharashtra, India.
Tel: +91-22-6794 2222
Email: jitendra.gandhi@wanbury.com

Anand Venugopal / Hanishi Shah
Adfactors PR
Oasis Complex, Kamala Mills Compound,
City Hall, Pandurang Budhkar Marg, Lower
Parel West, Mumbai – 400 021.
Tel: +91 7021852071 / +91 9619059339
Email: hanishi.shah@adfactorspr.com
anand.venugopal@adfactorspr.com

Disclaimer:

This document may contain statements which reflect management's current views and estimates and could be construed as forward-looking statements. The future involves certain risks and uncertainties and could cause actual results to differ materially from the current views being expressed. Potential risks and uncertainties include factors such as general economic conditions, foreign exchange fluctuation, pricing pressures, competition and regulatory developments.

